Interventional technology developer AngioDynamics has signed an agreement to acquire RadiaDyne, a private medical diagnostic and device company that develops patient radiation dose monitoring technology.
The deal will broaden AngioDynamics' oncology business, adding RadiaDyne's OARtrac radiation dose monitoring platform to its portfolio, the company said. RadiaDyne also makes IsoLoc/ImmobiLoc, endorectal tools that reduce prostate motion and radiation toxicity, and Alatus, a vaginal balloon packing system that improves dosimetry, according to AngioDynamics.
RadiaDyne's 12-month revenues exceeded $6 million. The acquisition is expected to close by the end of September, AngioDynamics said.
